Metabolic syndrome and male lower urinary tract symptoms
- PMID: 34859639
- DOI: 10.23736/S0031-0808.21.04496-7
Metabolic syndrome and male lower urinary tract symptoms
Abstract
Introduction: Historically, urologists regarded prostate enlargement as the sole cause for male bladder problems. Over time, subdivision of symptoms into storage, voiding and post-voiding symptoms raised awareness of the urinary tract fine-tuning associated with urine storage and voiding, and led to the umbrella term lower urinary tract symptoms (LUTS), which respects bladder and prostate function. While research goes on, it seems as if the more we know about urine storage and voiding, the more complicated it gets: different mechanism can mimic the same symptoms. Clinically, it remains ever the more challenging to understand the pathophysiological context of each patient. Metabolic syndrome (MetS), too, is an umbrella term. Metabolic changes caused by MetS pathophysiologically start with visceral adiposity. It leads to different changes in the signaling pathway including cytokines, elevated transmitters of inflammation, higher levels of free fatty acids (FFA), and adipokines, resulting in vasoconstriction, insulin resistance, impaired glucose uptake and high insulin secretion. Furthermore, MetS is thought to be associated with nephrolithiasis, BPH, LUTS, erectile dysfunction (ED), and infertility. This review aims at synthesizing interactions and consequences of LUTS with MetS.
Evidence acquisition: On May 31st, 2021, PubMed and Cochrane were searched with no language nor time restrictions, using the terms "Metabolic syndrome" and "male LUTS." A total of 252 publications were identified. Only papers that mentioned both terms either in their title or in their abstract were included. Hence, 120 papers were reviewed.
Evidence synthesis: Many different findings cause LUTS, which are summarized in the EAU Guidelines on male non-neurogenic LUTS. These different symptoms belong to different phases of bladder function. Frequency, nocturia, urgency and incontinence are symptoms of the filling phase, while hesitancy, intermittency, weak or irregular stream, straining and terminal dribble belong to the voiding phase of the bladder. Post-voiding symptoms include post-void dribbling and sensation of incomplete voiding. Symptoms of any phase of bladder function impair quality of life, and are associated with ageing.
Conclusions: Inflammation links both umbrella terms, LUTS and MetS. Understanding the exact role of the different elements will not only help to better understand both findings, but also lead to more efficacious treatment, and hopefully, in the future, personalized medicine, by understanding each individual's driving mechanism for LUTS. Reducing inflammation is likely to help patients with MetS and LUTS; further research could therefore focus on how to manage inflammation.
Similar articles
-
Obesity-initiated metabolic syndrome promotes urinary voiding dysfunction in a mouse model.Prostate. 2016 Aug;76(11):964-76. doi: 10.1002/pros.23185. Epub 2016 Apr 4. Prostate. 2016. PMID: 27040645 Free PMC article.
-
Prevalence and factors associated with uncomplicated storage and voiding lower urinary tract symptoms in community-dwelling Australian men.World J Urol. 2011 Apr;29(2):179-84. doi: 10.1007/s00345-010-0605-8. Epub 2010 Oct 21. World J Urol. 2011. PMID: 20963421
-
Definition and symptoms of underactive bladder.Investig Clin Urol. 2017 Dec;58(Suppl 2):S61-S67. doi: 10.4111/icu.2017.58.S2.S61. Epub 2017 Nov 13. Investig Clin Urol. 2017. PMID: 29279877 Free PMC article. Review.
-
A new experimental rat model of erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: the testosterone-supplemented spontaneously hypertensive rat.BJU Int. 2012 Nov;110(9):1352-8. doi: 10.1111/j.1464-410X.2012.11085.x. Epub 2012 Mar 27. BJU Int. 2012. PMID: 22448674
-
EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction.Eur Urol. 2015 Jun;67(6):1099-1109. doi: 10.1016/j.eururo.2014.12.038. Epub 2015 Jan 19. Eur Urol. 2015. PMID: 25613154 Review.
Cited by
-
The Role of 5-Phosphodiesterase Inhibitors (PDE-5I) in Current Benign Prostatic Hyperplasia Treatment: A Narrative Review.Medicina (Kaunas). 2024 Oct 23;60(11):1736. doi: 10.3390/medicina60111736. Medicina (Kaunas). 2024. PMID: 39596921 Free PMC article. Review.
-
Chemokine receptor 7 contributes to T- and B-cell filtering in ageing bladder, cystitis and bladder cancer.Immun Ageing. 2024 May 18;21(1):33. doi: 10.1186/s12979-024-00432-5. Immun Ageing. 2024. PMID: 38762550 Free PMC article.
-
An evaluation of lower urinary tract symptoms among patients with hypertension: A cross-sectional study.J Family Med Prim Care. 2024 Aug;13(8):3195-3202. doi: 10.4103/jfmpc.jfmpc_231_24. Epub 2024 Jul 26. J Family Med Prim Care. 2024. PMID: 39228634 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical